

PHARMACY COVERAGE GUIDELINE

ERLEADA™ (apalutamide) Generic Equivalent (if available)

This Pharmacy Coverage Guideline (PCG):

- Provides information about the reasons, basis, and information sources we use for coverage decisions
- Is not an opinion that a drug (collectively “Service”) is clinically appropriate or inappropriate for a patient
- Is not a substitute for a provider’s judgment (Provider and patient are responsible for all decisions about appropriateness of care)
- Is subject to all provisions e.g. (benefit coverage, limits, and exclusions) in the member’s benefit plan; and
- Is subject to change as new information becomes available.

Scope

- This PCG applies to Commercial and Marketplace plans
- This PCG does not apply to the Federal Employee Program, Medicare Advantage, Medicaid or members of out-of-state Blue Cross and/or Blue Shield Plans

Instructions & Guidance

- To determine whether a member is eligible for the Service, read the entire PCG.
 - This PCG is used for FDA approved indications including, but not limited to, a diagnosis and/or treatment with dosing, frequency, and duration.
 - Use of a drug outside the FDA approved guidelines, refer to the appropriate Off-Label Use policy.
 - The “Criteria” section outlines the factors and information we use to decide if the Service is medically necessary as defined in the Member’s benefit plan.
 - The “Description” section describes the Service.
 - The “Definition” section defines certain words, terms or items within the policy and may include tables and charts.
 - The “Resources” section lists the information and materials we considered in developing this PCG
 - **We do not accept patient use of samples as evidence of an initial course of treatment, justification for continuation of therapy, or evidence of adequate trial and failure.**
 - Information about medications that require prior authorization is available at www.azblue.com/pharmacy. You must fully complete the [request form](#) and provide chart notes, lab workup and any other supporting documentation. The prescribing provider must sign the form. Fax the form to BCBSAZ Pharmacy Management at (602) 864-3126 or email it to Pharmacyprecert@azblue.com.
-

Criteria:

- **Criteria for initial therapy:** Erleada (apalutamide) and/or generic equivalent (if available) is considered **medically necessary** and will be approved when **ALL** the following criteria are met:
 1. Prescriber is a physician specializing in the patient’s diagnosis or is in consultation with an Oncologist or Urologist
 2. Individual is 18 years of age or older
 3. Individual has a confirmed diagnosis of prostate cancer and used as **ONE** of the following:
 - a. Metastatic castration-sensitive prostate cancer (mCSPC)
 - b. Non-metastatic castration-resistant prostate cancer (nmCRPC)

ORIGINAL EFFECTIVE DATE: 03/15/2018 | ARCHIVE DATE: | LAST REVIEW DATE: 05/16/2024 | LAST CRITERIA REVISION DATE: 05/16/2024

BLUE CROSS®, BLUE SHIELD® and the Cross and Shield Symbols are registered service marks of the Blue Cross and Blue Shield Association, an association of independent Blue Cross and Blue Shield Plans. All other trademarks and service marks contained in this guideline are the property of their respective owners, which are not affiliated with BCBSAZ.

PHARMACY COVERAGE GUIDELINE

ERLEADA™ (apalutamide) Generic Equivalent (if available)

- c. Other request for a specific oncologic direct treatment use that is found and listed in the National Comprehensive Cancer Network (NCCN) Guidelines with Categories of Evidence and Consensus of 1 and 2A
4. Individual should also be receiving concurrently a gonadotropin-releasing hormone analog or have had a bilateral orchiectomy ([see Definitions section](#))
5. **If available:** Individual has failure after adequate trial, contraindication per FDA label, intolerance, or not a candidate for a **generic equivalent** [Note: Failure, contraindication or intolerance to the generic should be reported to the FDA] ([see Definitions section](#))
6. Individual has a baseline Eastern Cooperative Oncology Group Performance Status (ECOG) of 0-1

Initial approval duration: 6 months

➤ **Criteria for continuation of coverage (renewal request):** Erleada (apalutamide) and/or generic equivalent (if available) is considered **medically necessary** and will be approved when **ALL** the following criteria are met (**samples are not considered for continuation of therapy**):

1. Individual continues to be seen by a physician specializing in the patient's diagnosis or is in consultation with an Oncologist or Urologist
2. Individual's condition has responded while on therapy with response defined as there is no evidence of disease progression or unacceptable toxicity
3. Individual has been adherent with the medication
4. **If available:** Individual has failure after adequate trial, contraindication per FDA label, intolerance, or not a candidate for a **generic equivalent** [Note: Failure, contraindication or intolerance to the generic should be reported to the FDA] ([see Definitions section](#))
5. Individual has not developed any significant adverse drug effects that may exclude continued use such as:
 - a. Seizure
 - b. Cerebrovascular and ischemic cardiovascular event
 - c. Severe cutaneous adverse reaction

Renewal duration: 12 months

➤ Criteria for a request for non-FDA use or indication, treatment with dosing, frequency, or duration outside the FDA-approved dosing, frequency, and duration, refer to one of the following Pharmacy Coverage Guideline:

1. **Off-Label Use of Non-Cancer Medications**
2. **Off-Label Use of Cancer Medications**

ORIGINAL EFFECTIVE DATE: 03/15/2018 | ARCHIVE DATE: | LAST REVIEW DATE: 05/16/2024 | LAST CRITERIA REVISION DATE: 05/16/2024

BLUE CROSS®, BLUE SHIELD® and the Cross and Shield Symbols are registered service marks of the Blue Cross and Blue Shield Association, an association of independent Blue Cross and Blue Shield Plans. All other trademarks and service marks contained in this guideline are the property of their respective owners, which are not affiliated with BCBSAZ.

PHARMACY COVERAGE GUIDELINE

ERLEADA™ (apalutamide) Generic Equivalent (if available)

Description:

Erleada (apalutamide) is an androgen receptor inhibitor indicated for the treatment of patients with non-metastatic castration-resistant prostate cancer and for patients with metastatic castration-sensitive prostate cancer. Patients should also use of a gonadotropin-releasing hormone (GnRH) analog (also known as luteinizing hormone releasing hormone (LHRH) agonist or analog) **or** should have had bilateral orchiectomy.

Patients who do not achieve adequate suppression of serum testosterone (< 50 ng/dL) with medical or surgical castration can be considered for additional hormonal manipulations.

In the setting in which patients have no or minimal symptoms, administration of secondary hormonal therapy including addition of, or switching to, a different antiandrogen, addition of adrenal/paracrine androgen synthesis inhibitors, or use of an estrogen can be considered.

Definitions:

U.S. Food and Drug Administration (FDA) MedWatch Forms for FDA Safety Reporting
[MedWatch Forms for FDA Safety Reporting | FDA](#)

Castration-resistant prostate cancer (CRPC):

CRPC demonstrated during continuous ADT, defined as 3 PSA rises, at least 1 week apart, with the last PSA greater than (>) 2 nanogram per milliliter (ng/mL)

Prostate Specific Antigen Doubling Time (PSADT):

PSADT is calculated by using at least three prostate-specific antigen (PSA) values obtained during continuous ADT (androgen deprivation therapy)

Staging System for Prostate Cancer, excerpts:

N0 – No positive regional nodes

N1 – Metastases in regional lymph node(s)

M0 – No distant metastasis

M1 – Distant metastasis

M1a: Non-regional lymph node(s)

M1b: Bone(s)

M1c: Other site(s) with or without bone disease

[Note: When more than one site of metastasis is present, the most advanced category is used – M1c]

Gonadotropin-releasing hormone (GnRH) analogs or agonists: (Also referred to as luteinizing hormone releasing hormone (LHRH) agonists or analogs)

Zoladex (goserelin acetate) subcutaneous implant

Vantas (histrelin acetate) subcutaneous implant

ORIGINAL EFFECTIVE DATE: 03/15/2018 | ARCHIVE DATE: | LAST REVIEW DATE: 05/16/2024 | LAST CRITERIA REVISION DATE: 05/16/2024

BLUE CROSS®, BLUE SHIELD® and the Cross and Shield Symbols are registered service marks of the Blue Cross and Blue Shield Association, an association of independent Blue Cross and Blue Shield Plans. All other trademarks and service marks contained in this guideline are the property of their respective owners, which are not affiliated with BCBSAZ.

PHARMACY COVERAGE GUIDELINE

**ERLEADA™ (apalutamide)
Generic Equivalent (if available)**

Eligard (leuprolide acetate) subcutaneous injection
Lupron Depot (leuprolide acetate) intramuscular injection
Trelstar (triptorelin pamoate) intramuscular injection

Gonadotropin-releasing hormone antagonist:

Firmagon (dagarelix) subcutaneous injection
Orgovyx (relugolix)

Antiandrogens, oral: to maintain castrate serum levels of testosterone (< 50 ng/dL)

Zytiga (abiraterone acetate)
Erleada (apalutamide)
Casodex (bicalutamide)
Nubequa (darolutamide)
Xtandi (enzalutamide)
Flutamide
Nilandron (nilutamide)

ECOG Performance status:

Eastern Co-operative Oncology Group (ECOG) Performance Status	
Grade	ECOG description
0	Fully active, able to carry on all pre-disease performance without restriction
1	Restricted in physically strenuous activity but ambulatory and able to carry out work of a light or sedentary nature, e.g., light housework, office work
2	Ambulatory and capable of all selfcare but unable to carry out any work activities. Up and about more than 50% of waking hours
3	Capable of only limited selfcare, confined to bed or chair more than 50% of waking hours
4	Completely disabled. Cannot carry on any self-care. Totally confined to bed or chair
5	Dead

Oken, M.M., Creech, R.H., Tormey, D.C., Horton, J., Davis, T.E., McFadden, E.T., Carbone, P.P.: Toxicity And Response Criteria Of The Eastern Cooperative Oncology Group. Am J Clin Oncol 5:649-655, 1982

NCCN recommendation definitions:

Category 1:

Based upon high-level evidence, there is uniform NCCN consensus that the intervention is appropriate.

Category 2A:

Based upon lower-level evidence, there is uniform NCCN consensus that the intervention is appropriate.

Category 2B:

Based upon lower-level evidence, there is NCCN consensus that the intervention is appropriate.

Category 3:

Based upon any level of evidence, there is major NCCN disagreement that the intervention is appropriate



An Independent Licensee of the Blue Cross Blue Shield Association

PHARMACY COVERAGE GUIDELINE

ERLEADA™ (apalutamide) Generic Equivalent (if available)

Resources:

Erleada (apalutamide) product information, revised by Janssen Products, LP. 12-2023. Available at DailyMed <http://dailymed.nlm.nih.gov>. Accessed April 10, 2024.

Dawson NA. Overview of the systemic treatment of advanced, recurrent and metastatic castration-sensitive prostate cancer In: UpToDate, Vogelzang N, Lee WR, Richie JR, Vora SR (Eds), UpToDate, Waltham MA.: UpToDate Inc. Available at <http://uptodate.com>. Literature current through March 2024. Topic last updated January 10, 2024. Accessed April 10, 2024.

Dawson NA, Leger P. Overview of the treatment of castration-resistant prostate cancer (CRPC). In: UpToDate, Vogelzang N, Lee WR, Richie JR, Sartor AO, Vora SR (Eds), UpToDate, Waltham MA.: UpToDate Inc. Available at <http://uptodate.com>. Literature current through March 2024. Topic last updated October 05, 2023. Accessed April 10, 2024.

National Comprehensive Cancer Network (NCCN) Clinical Practice Guidelines in Oncology (NCCN Guidelines®): Prostate Cancer Version 3.2024 – Updated March 08, 2024. Available at <https://www.nccn.org>. Accessed April 10, 2024.

Off Label Use of Cancer Medications: A.R.S. §§ 20-826(R) & (S). Subscription contracts; definitions.

Off Label Use of Cancer Medications: A.R.S. §§ 20-1057(V) & (W). Evidence of coverage by health care service organizations; renewability; definitions.

ORIGINAL EFFECTIVE DATE: 03/15/2018 | ARCHIVE DATE: | LAST REVIEW DATE: 05/16/2024 | LAST CRITERIA REVISION DATE: 05/16/2024

BLUE CROSS®, BLUE SHIELD® and the Cross and Shield Symbols are registered service marks of the Blue Cross and Blue Shield Association, an association of independent Blue Cross and Blue Shield Plans. All other trademarks and service marks contained in this guideline are the property of their respective owners, which are not affiliated with BCBSAZ.